Journal
TRANSLATIONAL RESEARCH
Volume 220, Issue -, Pages 57-67Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2020.03.006
Keywords
-
Categories
Funding
- Merck
- Nivalis
- Cubist
- Mead Johnson
- Rebiotix
- BioFire
- Assembly BioSciences
- NIAID [U01-AI124290]
- NIDDK [P30-DK56338]
Ask authors/readers for more resources
Clostridioides difficile infection (CDI) is an urgent threat to global public health. Patient susceptibility to C. difficile is highly dependent on host immune status and gut dysbiosis resulting in loss of protective microbiota consortia that prevent spore germination, pathogen colonization, and disease pathogenesis. Recent clinical studies highlight the problems of differentiating symptomatic CDI from asymptomatic C. difficile carriage in patients with diarrhea. In this review, we consider how integration of microbiome and host immune systems biology data may aid in the clinical diagnosis of CDI when validated against gold standard testing and combined with standard microbiology laboratory assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available